The abstract is read at the publisher; the summary is JClub's.
RIPK1 activation drives pathogenic GRANZYME hi CXCR5 hi double-negative T-cell expansion in preclinical ALPS mouse models, and RIPK1 inhibition blocks DNT generation and organ burden.
- Why it matters: ALPS severity tracks with aberrant DNT expansion, but the mechanisms that generate pathogenic DNT cells and enable their tissue infiltration were unclear.
- What they did: Single-cell transcriptomics of pediatric ALPS peripheral blood identified a conserved pathogenic effector DNT subset; in an apoptosis-defective murine ALPS model, RIPK1 inhibition (genetic or pharmacologic) was tested, alongside CREM-mediated CD8 silencing assays.
- The result: Peripheral CD8+ T cells from patients and ALPS mouse models were linked to activation-induced conversion into pathogenic DNT cells, which RIPK1 inhibition effectively blocked; in mice, RIPK1 kinase inhibition reduced DNT burden, reversed cytopenias, and alleviated autoimmune pathology.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.